Press release
Health Care
November 10, 2020

Evonik launches EUDRAGIT® ready-to-use powder premix to improve processing, appearance and swallowability of oral drug products with an immediate release profile

  • EUDRAGIT® IR ReadyMix White requires half the processing time of HPMC or PVA-based ready-to-use alternatives
  • High-gloss coating with superior swallowability and tablet taste-masking to enhance brand acceptability and preference
  • Extends Evonik’s market-leading portfolio of oral drug delivery solutions for immediate, delayed and sustained release

Evonik, a global leader for advanced drug delivery, today launched a new ready-to-use powder premix blend of its EUDRAGIT® functional polymers used for oral products with an immediate release profile.

EUDRAGIT® IR ReadyMix White is fast and easy-to-process, with a high-gloss coating delivering an elegant optical appearance and superior swallowability outcomes. As a fully formulated, powder premix blend of EUDRAGIT® E PO that meets the requirements of all major pharmacopoeias, it is readily available for shipment as a standard product.

“EUDRAGIT® has been the world’s preferred brand of functional polymers used with oral drug products for more than 60 years,” said Matthias Wiehn, Global Product Manager of Evonik’s Oral Drug Delivery Solutions business. “With the launch of EUDRAGIT® IR® ReadyMix White, pharmaceutical companies now have an immediate and attractive choice to optimize the processability, appearance, taste and swallowability of drug products with an immediate release profile.”

EUDRAGIT® IR ReadyMix White is suitable for use with tablets and a range of other solid oral dosage forms. Due to its high solid content and low processing temperature, the premix can be processed in around half the time as HPMC or PVA-based ready-to-use alternatives which reduces cost and improves batch productivity. In addition to having a visually elegant high-gloss coating, its non-sticky behaviour and intactness while inside the mouth can help to enhance swallowability.

EUDRAGIT® IR ReadyMix White is the second ready-to-use premix blend developed by Evonik for use with oral drug products with an immediate release profile. Evonik’s first ready-to-use premix product known as EUDRAGIT®E PO ReadyMix shares many of the same processing and rapid dissolution advantages as EUDRAGIT® IR ReadyMix White, but is custom tailored for use with oral drug products requiring superior colour matching, moisture protection or taste masking outcomes.

EUDRAGIT® is the industry’s preferred portfolio of functional polymers for use with oral drug products that have an immediate, delayed or sustained release profile. The breadth, versatility and history of EUDRAGIT®, combined with Evonik’s range of drug delivery technologies, formulation and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety and functional reliability for their oral solid dosage forms.

Evonik’s Health Care business line, which is part of the Nutrition and Care division of Evonik, is one of the world’s leading CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest pharmaceutical suppliers of generic APIs, amino acids and cell culture ingredients, and a top 3 global CMO for APIs and intermediates.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.